The Dementia Consortium is supporting a project led by Dr David Brough to develop novel therapeutics for Alzheimer’s disease targeting the immune system.
15 March 2017
MRC Technology has licensed an antibody to Newsummit Biopharma for development of a novel therapeutic for treatment of Hepatitis C virus (HCV) infection.
14 March 2017
MRC Technology joins project UTILE to enable medical breakthroughs from European funded research
MRC Technology is committed to ensuring that promising medical research is protected and progressed to benefit patients. We are therefore pleased to announce that we are funding partners in an international technology transfer consortium set up to enable translation of health research into new diagnostics and medicines. The UTILE Project will facilitate partnering and licensing opportunities for research funded under the Seventh Framework Programme (FP7) Health and Societal Challenge 1 of Horizon 2020.
UTILE, a Horizon 2020 funded project, will develop an online marketplace to bring together innovation providers and innovation developers, combining technology push and market pull approaches. It aims to add value to promising research to maximise results. UTILE will also provide recommendations to the European Commission for future research and technology transfer within the health sector.
The international consortium is led by PNO Consultants BV (NL) and includes technology transfer organisations: Ascenion GmbH (DE); ASTP Proton (NL); Bergen Teknologioverforing AS (BTO) (NO); Karolinska Institutet Innovations AB (SE); MRC Technology (UK); Tech Transfer Summit Ltd. (UK); and commercial organisations: Ciaotech Srl (IT); Europroject Ood (BG); Europe Unlimited SA (BE); and Innovation Engineering Srl (IT). The US National Institute of Health (NIH) is also actively involved in the project.
24 February 2017
MRC Technology has appointed Steve Visscher CBE to its board of trustees.
30 January 2017
Cancer Research UK, Cancer Research Technology and MRC Technology are joining forces to identify and validate novel drug discovery targets that could lead to new immunotherapy treatments.
18 January 2017
MRC Technology has announced the relocation of its Centre for Diagnostics Development (CDD) to Nine, Edinburgh BioQuarter. The move forms part of the charity’s investment of over £7million over the next five years to further its work accelerating diagnostic research into the clinic.
17 January 2017
by Mike Johnson (First appeared on AMRC website, 21 November 2016) Which treatment or diagnostic would make a patient’s life better? This is the starting point of what MRC Technology does. Like other medical research charities, we exist to improve patients’ lives, but unlike them, we don’t focus on a specific disease but work across a range of diseases. Many charities are doing tremendous work to support patients and fund research into potential treatments. If we work together, we can create a much bigger wave towards positive… Read More
22 November 2016
Dr David Pardoe, Head of Growth Projects at MRC Technology (First appeared as part of MediaPlanet’s antibiotic resistance campaign) Antibiotic resistance As we face the prospect of living in a ‘post-antibiotic’ era, there is renewed urgency to rethink the way we approach both the research and the funding of drug innovation. When it comes to developing new drugs we typically build on the research we’ve done in the past. But in fighting gram-negative bacteria we’ve already tested everything that is likely to work, so we need a new approach.With… Read More
18 November 2016
New research consortium aims to identify opportunities for drug discovery through the innovative use of antibodies in structure-based drug discovery and design.
8 November 2016
MRC Technology and aPODD have launched a call for action to accelerate the development of new treatments for children with cancer. Around 1,500 children are diagnosed with cancer in the UK every year, and 300 will die from the disease.
20 October 2016